Fibolac10 gm/sachet

Fibolac is an osmotic laxative with the following evidence-based uses:

• Chronic idiopathic constipation (established/approved use): Used in adults for relief of chronic constipation, improving stool frequency and consistency.
• Hepatic encephalopathy (guideline-supported use): Used to lower blood ammonia levels and manage symptoms of hepatic encephalopathy, including prevention of recurrent episodes in patients with chronic liver disease.
• Bowel preparation adjunct (adjunct use): Sometimes used as part of bowel cleansing regimens prior to certain procedures, generally in combination with other measures.

Fibolac is not intended for occasional, short-term constipation where simpler measures (diet, fluids, activity) would suffice.

Fibolac is a semi-synthetic disaccharide (a sugar alcohol derived from lactose, composed of galactose and sorbitol) that is not significantly hydrolyzed or absorbed in the upper gastrointestinal tract. It reaches the colon largely unchanged, where it is fermented by colonic bacteria to produce an osmotic and acidifying effect. Structurally and functionally, Fibolac is closely related to lactulose and is classified as an osmotic laxative.

Fibolac belongs to the osmotic laxative class, specifically the non-absorbable disaccharide/sugar-alcohol subgroup, similar in mechanism to lactulose.

Lactitol Monohydrate passes through the small intestine largely unabsorbed and unchanged. In the colon, it is metabolized by resident bacteria into short-chain organic acids (e.g., acetic, lactic, and propionic acids). This produces two key effects:

• Osmotic effect: The unmetabolized sugar and its breakdown products increase osmotic pressure within the colon, drawing water into the lumen, softening stool, and increasing stool volume and frequency, which stimulates peristalsis (laxative effect).
• Ammonia-lowering effect: Colonic acidification favors conversion of absorbable ammonia (NH3) to poorly absorbable ammonium ion (NH4+), reducing blood ammonia levels; the resulting catharsis also reduces colonic bacterial ammonia production and enhances nitrogen excretion in stool, which is the basis for its use in hepatic encephalopathy.

Onset of the laxative effect with Lactitol Monohydrate is typically within 1 to 3 days of regular use.

Fibolac powder should be fully dissolved in water, juice, or a similar liquid, or mixed into soft food, and taken orally, preferably with a meal. Take other oral medicines at least 2 hours apart from Fibolac where possible.

Fibolac may reduce the absorption of other concurrently administered oral medications due to its effect on gastrointestinal transit time and osmotic activity; separating dosing by at least 2 hours is generally advised.

Concomitant use with other laxatives may increase the risk of excessive bowel movements, dehydration, and electrolyte disturbances. Caution is advised when Fibolac is used with drugs that affect electrolyte balance (e.g., diuretics, corticosteroids), given the theoretical risk of additive fluid/electrolyte loss with excessive use.

The most common side effects of Fibolac, especially at the start of treatment, include:

• Flatulence
• Abdominal cramping, bloating, or distension
• Diarrhea or loose stools (usually dose-related and improves with dose adjustment)

These effects are usually mild and tend to improve with continued use or dose reduction. Less commonly, hypersensitivity reactions (such as rash or itching) have been reported. Excessive or prolonged use can lead to significant fluid and electrolyte disturbances (see Precautions and Warnings).

Fibolac is minimally absorbed systemically. Animal reproduction studies have not shown evidence of fetal harm; however, adequate and well-controlled studies in pregnant women are lacking. Fibolac should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Because systemic absorption is minimal, clinically significant exposure of a breastfeeding infant is considered unlikely, but data are limited. Use during breastfeeding only under medical advice.

Use Fibolac with caution in the following situations:

• Diabetes mellitus: Fibolac contains small amounts of fermentable sugars; although systemic absorption is minimal, blood glucose control should be monitored, especially with prolonged use.
• Fluid and electrolyte imbalance: Excessive or prolonged use of Fibolac can cause significant diarrhea leading to dehydration and electrolyte disturbances (e.g., low potassium or sodium); use the lowest effective dose and monitor patients who are elderly, debilitated, or have renal/cardiac impairment.
• Undiagnosed abdominal pain: Avoid use in patients with acute abdominal symptoms of unknown cause until a serious condition (e.g., obstruction, appendicitis) has been excluded.
• Hepatic encephalopathy titration: Requires close medical supervision to avoid excessive catharsis while achieving adequate ammonia control.

Overdose with Fibolac may cause severe diarrhea, abdominal cramping, and consequent dehydration and electrolyte imbalance. If overdose is suspected, discontinue Fibolac and seek immediate medical attention or contact a poison control center. Management is supportive, focused on fluid and electrolyte replacement; there is no specific antidote.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment: No specific dose adjustment is established, but caution is advised due to increased risk of fluid/electrolyte disturbance with excessive use; monitor closely.

Hepatic impairment: Fibolac is commonly used specifically in patients with hepatic impairment for hepatic encephalopathy; dosing is titrated individually under medical supervision.

Elderly: Use with caution, monitoring for dehydration and electrolyte imbalance, as this population may be more susceptible to fluid loss from osmotic diarrhea.

Pediatric use: Safety and effectiveness of Fibolac have not been formally established in pediatric patients for chronic constipation; use only under direct medical supervision if prescribed.

Duration of treatment with Fibolac depends on the indication. For chronic constipation, it may be used for as long as needed under medical guidance, with periodic reassessment. For hepatic encephalopathy, it is typically used long-term/chronically to prevent recurrence, with dose titrated to maintain 2-3 soft stools per day.

Lactitol Monohydrate is classified as an osmotic laxative (non-absorbable disaccharide/sugar alcohol).

Lactitol Monohydrate works by remaining largely unabsorbed in the small intestine and passing into the colon, where colonic bacteria ferment it into organic acids. This lowers colonic pH, draws water into the bowel lumen through an osmotic effect (softening stool and increasing bowel movements), and converts absorbable ammonia into non-absorbable ammonium, thereby reducing blood ammonia concentrations relevant to hepatic encephalopathy.

The safety and effectiveness of Fibolac have not been formally established in pediatric patients. Use in children should only occur under direct physician supervision, with dosing individualized based on clinical judgment, when a treating physician determines the benefit outweighs the risk.